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A B S T R A C T
Objectives: The epidemiology of disease caused by group B Streptococcus (GBS; Streptococcus agalactiae)
outside pregnancy and the neonatal period is poorly characterized. The aim of this study was to quantify
the role of GBS as a cause of surgical site and non-invasive infections at all ages.
Methods: A systematic review (PROSPERO CRD42017068914) and meta-analysis of GBS as a proportion
(%) of bacterial isolates from surgical site infection (SSI), skin/soft tissue infection (SSTI), urinary tract
infection (UTI), and respiratory tract infection (RTI) was conducted.
Results: Seventy-four studies and data sources were included, covering 67 countries. In orthopaedic
surgery, GBS accounted for 0.37% (95% conﬁdence interval (CI) 0.08–1.68%), 0.87% (95% CI 0.33–2.28%),
and 1.46% (95% CI 0.49–4.29%) of superﬁcial, deep, and organ/space SSI, respectively. GBS played a more
signiﬁcant role as a cause of post-caesarean section SSI, detected in 2.92% (95% CI 1.51–5.55%), 1.93% (95%
CI 0.97–3.81%), and 9.69% (95% CI 6.72–13.8%) of superﬁcial, deep, and organ/space SSI. Of the SSTI
isolates, 1.89% (95% CI 1.16–3.05%) were GBS. The prevalence of GBS in community and hospital UTI
isolates was 1.61% (1.13–2.30%) and 0.73% (0.43–1.23%), respectively. GBS was uncommonly associated
with RTI, accounting for 0.35% (95% CI 0.19–0.63%) of community and 0.27% (95% CI 0.15–0.48%) of
hospital RTI isolates.
Conclusions: GBS is implicated in a small proportion of surgical site and non-invasive infections, but a
substantial proportion of invasive SSI post-caesarean section.
© 2019 The Authors. Published by Elsevier Ltd on behalf of International Society for Infectious Diseases.
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-
nc-nd/4.0/).
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Streptococcus agalactiae (group B Streptococcus, GBS) is impli-
cated in a range of clinical presentations, including skin and soft
tissue infections (SSTI) and urinary tract infections (UTI) (Kerneis
et al., 2017; Chaiwarith et al., 2011; Falagas et al., 2006). GBS disease
in adults is of growing clinical and public health concern$ Institution at which work completed: Public Health England.
* Corresponding author at: Healthcare-Associated Infection and Antimicrobial
Resistance (HCAI & AMR) Division, National Infection Service, Public Health
England, 61 Colindale Avenue, London NW9 5EQ, UK.
E-mail address: simon.collin@phe.gov.uk (S.M. Collin).
https://doi.org/10.1016/j.ijid.2019.04.017
1201-9712/© 2019 The Authors. Published by Elsevier Ltd on behalf of International So
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).(Bjornsdottir et al., 2016; Lamagni et al., 2013; Skoff et al., 2009),
and the increasing prevalence of risk factors for GBS disease
including old age and diabetes (Ballard et al., 2016; Camuset et al.,
2015; Lefebvre et al., 2007; Huang et al., 2006) implies considerable
health and social care costs (Badia et al., 2017; Kennedy et al., 2013;
Ciani et al., 2013; Allegranzi et al., 2011). The advent of vaccines to
prevent neonatal GBS disease raises the possibility of preventing GBS
disease in other patient groups (Kim et al., 2017; Heath et al., 2017;
Vekemans et al., 2018). Whilst the worldwide burden of maternal
and infant GBS disease has been quantiﬁed (Madrid et al., 2017; Le
Doare et al., 2017; Russell et al., 2017a; Hall et al., 2017; Tann et al.,
2017; Kohli-Lynch et al., 2017; Bianchi-Jassiret al., 2017; Russell et al.,
2017b; Seale et al., 2017a; Seale et al., 2017b), the burden of other
forms of GBS disease is unknown (Le Doare and Heath, 2013).ciety for Infectious Diseases. This is an open access article under the CC BY-NC-ND
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GBS as a cause of surgical site, healthcare-associated, and non-
invasive bacterial infections. All types of surgical site infection (SSI)
were included, namely superﬁcial, deep, and organ/space, along
with catheter-associated UTI and ventilator-associated pneumonia
(VAP). For other types of infection, ‘non-invasive’ was deﬁned by
excluding infections where GBS was detected at a sterile site.
Infections where GBS was detected in urine were included because
UTIs are relatively common in the population and the overall
proportion attributable to GBS is unquantiﬁed.
Methods
This review was registered with PROSPERO (CRD42017068914).
Scoping reviews showed that the incidence of GBS has rarely been
reported; hence, the primary outcome was GBS as a proportion of
the total number of bacterial isolates for each type of infection.
Searches
The types of infection were not pre-speciﬁed, but the search
strategy aimed to capture epidemiological studies and surveillance
sources of surgical site, healthcare-associated, skin/soft tissue/
wound, urinary tract, and respiratory tract infections (RTI). The
following databases and libraries were searched: MEDLINE,
Embase, CINAHL, Scopus, Global Health, and Trip (including DARE
and Cochrane). Full search terms are provided as Supplementary
Material. In brief, medical subject heading (MeSH) search termsFigure 1. Study selection (Pfor “Bacterial Infections”, “Microbial Sensitivity Tests”, “Cross
Infection”, “Soft Tissue Infections”, “Urinary Tract Infections”,
“Respiratory Tract Infections”, “Wound Infections”, or “Streptococ-
cus agalactiae” were used in conjunction with text word terms for
healthcare-associated, surgical, or community infection or group
B/haemolytic streptococcal infection. Studies with title words
indicating a focus on non-surgical invasive infection (bloodstream,
endocarditis, meningitis, sepsis, or bacteraemia) were excluded.
The search was restricted to publication dates from January 1, 2000
to July 5th 2017 and to studies in humans. There was no language
restriction.
Screening and extraction
Citations identiﬁed by the search were imported into EndNote
(EndNote X8; Clarivate Analytics, Boston, MA, USA) for de-
duplication, and then imported into EPPI-Reviewer (EPPI-Reviewer
4; EPPI-Centre Software; Social Science Research Unit, UCL
Institute of Education, London, UK) for further de-duplication.
One reviewer (SC) conducted a ﬁrst screen by title and abstract;
two reviewers (SC and TL) then conducted a second screen by title
and abstract independently and in parallel, and disagreements
were resolved with a third reviewer (NS). Full texts of all articles
identiﬁed in the second screen by title and abstract were retrieved.
These were screened for ﬁnal inclusion by one reviewer (SC)
concurrently with data extraction. A second reviewer (TL)
independently checked inclusion/exclusion and data extraction
from a randomly selected sample (10%) of full texts.RISMA ﬂow diagram).
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The methodological quality of included studies was rated by
two reviewers (SC 100%, TL 10%) using a nine-item quality
assessment tool adapted from the National Institutes of Health
Quality Assessment Tool for Observational Cohort and Cross-
Sectional Studies (see Supplementary Material). The adaptation
allowed for the assessment of the quality of data from surveillance
systems and studies based on routine laboratory data, which
comprised the majority of the included data sources. Each source/
study was rated as being of ‘good’, ‘fair’, or ‘poor’ quality. Data were
not extracted from sources/studies that were rated ‘poor’.
Other data sources
If a study did not report data at the level of detail required for
the meta-analyses, e.g. pathogens reported solely as ‘Streptococcus
spp’ or ‘Other’, or aggregated data for all types of surgical site
infection, the authors were contacted to request data. If unpub-
lished data were provided that superseded data reported in
retrieved texts, the most relevant or recent reference was retained
as the citation or an additional reference was included as
‘identiﬁed through other sources’. Three institutions that publish
routine surveillance data were identiﬁed prior to the review as
potential sources of data: Public Health England (PHE), the
European Centre for Disease Prevention and Control (ECDC), and
the US Centers for Disease Control and Prevention (CDC).
Meta-analysis
Binomial-normal random-effects meta-analysis of GBS as a
proportion of all isolated microorganisms was performed in Stata
Release 13, 2013 (StataCorp., College Station, TX, USA) using
‘metaprop_one’ (Nyaga et al., 2014). In this approach, the binomial
distribution is used to model within-study variability, and the normal
distribution is used to model the random effects. Between-study
heterogeneity was estimated ast2, and evidence of heterogeneity was
tested by likelihood ratio (LR) test comparing random- and ﬁxed-
effects models. The proportion of overall heterogeneity attributable to
between-study variance was quantiﬁed using a formulation of the I2
statistic for binary variables (Zhou and Dendukuri, 2014). Prediction
intervals were estimated to show the expected prevalence of GBS
taking into account between-study variability (IntHout et al., 2016;
Nagashima et al., 2018). Meta-analysis defaulted to ﬁxed-effects if
three or fewer studies were included. Subgroup analyses speciﬁed a
priori were: age group (neonatal, child, adult, elderly); surgicalTable 1
Studies/sources contributing data to the meta-analyses for each type of infection.
Type of
infection
Number of studies/
data sourcesa
Number of
countries
Quality rating T
e
Good Fair Poor
Surgical site 17 38 14
(82.4%)
3
(17.6%)
0
(0.0%)
8
Skin and soft
tissue
14 60 10
(71.4%)
4
(28.6%)
0
(0.0%)
2
Urinary 42 45 32
(76.2%)
10
(23.8%)
0
(0.0%)
5
Respiratory 17 38 12
(70.6%)
5
(27.8%)
0
(0.0%)
2
Ear 2 1 2
(100.0%)
0
(0.0%)
0
(0.0%)
2
Eye 6 9 3
(50.0%)
3
(50.0%)
0
(0.0%)
6
GBS, group B Streptococcus.
a Fourteen of the 74 sources provided data on more than one type of infection.
b Some sources contributed multiple estimates of the prevalence of GBS, e.g. from sspecialty, type of SSI (superﬁcial incisional, deep incisional, or
organ/space) (Owens and Stoessel, 2008); and putative origin of
infection (community, hospital, device/procedure).
Role of the funding source
The funder of the study (Pﬁzer Inc.) had no role in the study
design, data collection, data analysis, data interpretation, or
writing of the report. The corresponding author had full access
to the data in the study and ﬁnal responsibility for the decision to
submit this paper.
Results
Database searches identiﬁed 10 879 references (Figure 1); 349
were retained for full-text review, of which 63 were included for
data extraction and meta-analysis. Agreement between the two
reviewers at the title/abstract and full-text screening stages was
92% (26/340) and 91% (32/35), respectively. The 63 full-text
references included two relating to data sources identiﬁed prior to
the review, namely CDC (SSI, UTI, and RTI data) (Weiner et al.
(2016)) and PHE (SSI data) (Elgohari et al., 2017). ECDC SSI
(European Centre for Disease Prevention and Control (ECDC),
2016), ECDC point prevalence survey (PPS) of healthcare-associat-
ed infections (HAI) in acute hospitals (European Centre for Disease
Prevention and Control (ECDC), 2013), and ECDC intensive care
unit (ICU) HAI data (European Centre for Disease Prevention and
Control (ECDC), 2017) are summarized in reports, but no published
record could be found for PHE UTI data. These four additional data
sources (three ECDC, one PHE) were included as ‘identiﬁed prior to
review’; a further seven ‘additional records/data sources’ were
identiﬁed during full-text screening (Bouza et al., 2001a; Canadian
Antimicrobial Resistance Alliance (CARA), 2016; Lee et al., 2004;
Morris et al., 2015; Santé publique France, 2016; Stapleton et al.,
2007; Garau et al., 2013) (Figure 1). The total number of included
studies and data sources (hereafter referred to as ‘sources’) was 74
(Table 1, Figure 1), representing 67 countries (Figure 2); 77% (57/
74) were rated good quality and 23% (17/74) fair quality (83%
agreement) (see Supplementary Material).
Types of infection
The six foci of infection that emerged from the review were
surgical site (17 sources), skinandsoft tissue(14 sources), urinary(42
sources), respiratory (17 sources), ear (two sources), and eye (six
sources). SSI were deﬁned in the majority of sources according tootal number of
stimates includedb
Total number of isolates/
infections
Total number of GBS
isolates/ infections
7 224 544 2634
7 181 575 3842
7 2 820 252 49 609
3 39 181 171
 264 0
 5981 30
everal settings, cohorts, countries, or time periods.
Figure 2. Countries represented in included studies.
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superﬁcial incisional (involving only skin and subcutaneous tissue
of the incision), deep incisional (involving deep soft tissue of the
incision, e.g. fascia/muscle), and organ/space (involving any part of
the anatomy deeper than the fascial/muscle layers, e.g. organ, breast,
spinal or intracranial abscess, bone, joint or bursa, myo-, peri- or
endocardium, intra-abdominal, arterial or venous) (Owens and
Stoessel, 2008; Horan et al., 2008). UTI case deﬁnitions varied more
widely, but typically required >105 CFU/ml or >104 CFU/ml with
symptoms or leukocyturia. Community- vs. healthcare-associated
UTI and RTI were differentiated either by time since admission
(<48 h for community), specimen source (primary vs. secondary or
tertiary care), or if reported as healthcare-associated, e.g. catheter-
associated urinary tract infection (CAUTI) and VAP. There was
considerable variation across sources of SSTI data: some focused on
complicated SSTI (cSSTI), deﬁned as requiring surgical intervention,
involving deeper soft tissue oroccurring in an immunocompromised
patient (Montravers et al., 2013); some included wound and surgical
site infection; some included isolates from a range of specimens
(including blood). The proportions of studies that accounted for
polymicrobial infections, i.e. where the denominator was the total
number of isolates, rather than reporting only one isolate per
infection, were 88%(15/17) for SSI, 50% (7/14) for SSTI,60% (25/42) for
UTI, and 65% (11/17) for RTI. Fourteen of the 74 sources provided data
on more than one type of infection, and some contributed multiple
estimates of the prevalence of GBS to each meta-analysis, e.g. from
several settings, cohorts, countries, or time periods.
Surgical site infection
Seventeen sources of SSI data were included (Weiner et al., 2016;
Elgohari et al., 2017; European Centre for Disease Prevention and
Control (ECDC), 2016; Morris et al., 2015; Santé publique France,
2016; Cossin et al., 2015; Deptula et al., 2017; Fong et al., 2015; Jeong
et al., 2013; Jodra et al., 2006; Kim et al., 2012; Phu et al., 2016;Rennert-May et al., 2016; Sabra and Abdel-Fattah, 2012; Song et al.,
2012; Worth et al., 2015; Mannien et al., 2007), six of which were
disaggregated by type of SSI (Elgohari et al., 2017; European Centre
for Disease Prevention and Control (ECDC), 2016; Morris et al., 2015;
Jodra et al., 2006; Worth et al., 2015; Mannien et al., 2007). GBS
represented 0.73% (95% conﬁdence interval (CI) 0.40–1.34%) of SSI
isolates from all types of surgery (Table 2). The highest prevalence of
GBS was in obstetrics/gynaecology (including caesarean section):
GBS represented 3.50% (95% CI 2.14–5.67%) of isolates of any SSI type,
3.87% (95% CI 1.82–8.00%) of superﬁcial SSI isolates, 3.80% (95% CI
1.82–7.76%) of deep incisional isolates, and 10.5% (95% CI 6.86–15.7%)
of organ/space isolates (Table 2). For caesarean section, the
prevalence of GBS among all SSI isolates was 3.49% (95% CI 1.99–
6.06%), increasing from 2.92% (95% CI 1.51–5.55%) for superﬁcial and
1.93% (95% CI 0.97–3.81%) for deep SSI to 9.69% (95% CI 6.72–13.8%)
for organ/space SSI (between-subgroups p < 0.01) (Figure 3). A
similar trend towards a higher prevalence of GBS in invasive
compared with superﬁcial SSI was seen for orthopaedic surgery
(Figure 4), but not for abdominal or cardiac surgery (Table 2).
GBS accounted for 2.40% (95% CI 1.89–3.05%) of isolates from SSI
after vascular surgery, 1.23% (95% CI 0.84–1.79%) of breast surgery
SSI isolates, and 1.14% (95% CI 0.51–2.53%) of orthopaedic surgery
SSI isolates (Table 2, Supplementary Material Figures). For other
types of surgery where more than one data source was identiﬁed
(abdominal, cardiac, neuro/cranial, prostate), the prevalence of
GBS was 0.25%. Data were available from only a single source
(CDC) (Weiner et al., 2016) for kidney, neck, and transplant surgery.
Of 18 subgroup meta-analyses by surgical category and SSI type
(Table 2), 10 had evidence (p  0.01) of between-study heteroge-
neity, representing 10–25% of variance in prevalence estimates.
Skin and soft tissue infection
Fourteen sources of data on SSTI were included (European
Centre for Disease Prevention and Control (ECDC), 2013; Canadian
Table 2
Streptococcus agalactiae as a percentage of surgical site infection (SSI) isolates.
Surgical
category
Superﬁcial incisional Deep incisional Organ/space All types of SSI
Estimates
included, n
Pooled %
prevalence
(95% CI)
I2
(p-Value)
Estimates
included, n
Pooled %
prevalence
(95% CI)
I2
(p-Value)
Estimates
included, n
Pooled %
prevalence
(95% CI)
I2
(p-Value)
Estimates
included, n
Pooled %
prevalence
(95% CI)
I2
(p-Value)
Various (not
speciﬁed)
5 0.74 (0.64–0.86)
t2 = 0.00
0.0%
(p =1.00)
Abdominala 15 0.23 (0.05–1.08)
t2 = 1.92
11.2%
(p<0.01)
12 0.37 (0.08–1.76)
t2 = 1.43
15.5%
(p<0.01)
12 0.19 (0.04–0.84)
t2 = 1.40
11.7%
(p =0.01)
19 0.25 (0.10–0.63)
t2 = 1.03
16.2%
(p<0.01)
Breast 4 1.23 (0.84–1.79)
t2 = 0.00
0.0%
(p =1.00)
Cardiacb 11 0.17 (0.07–0.41)
t2 = 0.00
0.0%
(p =1.00)
9 0.18 (0.03–0.96)
t2 = 1.23
4.1%
(p= 0.10)
7 0.18 (0.05–0.73)
t2 = 0.00
0.0%
(p =1.00)
12 0.22 (0.07–0.69)
t2 = 1.23
12.3%
(p<0.01)
Obs/Gync
Inc. C-section 3 3.87 (1.82–8.00)
t2 = 0.39
– 2 3.80 (1.82–7.76) – 3 10.5 (6.86–15.7)
t2 = 0.00
– 5 3.50 (2.14–5.67)
t2 = 0.30
85.6%
(p<0.01)
Exc. C-section 3 3.12 (1.41–6.78)
t2 = 0.00
– 2 8.11 (2.64–22.3) – 2 6.06 (1.52–21.2) – 3 3.94 (2.30–6.67)
t2 = 0.00
–
Caesarean
section
13 2.92 (1.51–5.55)
t2 = 0.41
27.6%
(p<0.01)
7 1.93 (0.97–3.81)
t2 = 0.00
0.0%
(p=1.00)
7 9.69 (6.72–13.8)
t2 = 0.00
0.13%
(p =0.50)
15 3.49 (1.99–6.06)
t2 = 0.31
27.2%
(p<0.01)
Kidney 1 0.00 (0.00–1.33) –
Neckd 1 0.47 (0.08–2.62) –
Neuro/craniale 4 0.20 (0.09–0.49)
t2 = 0.00
0.0%
(p =1.00)
Orthopaedicf 13 0.37 (0.08–1.68)
t2 = 1.74
14.3%
(p<0.01)
12 0.87 (0.33–2.28)
t2 = 0.78
25.4%
(p<0.01)
11 1.46 (0.49–4.29)
t2 = 1.20
23.5%
(p<0.01)
17 1.14 (0.51–2.53)
t2 = 1.14
45.3%
(p<0.01)
Prostate 2 0.00 (0.00–0.08) –
Transplantg 1 0.25 (0.07–0.89) –
Vascularh 4 2.40 (1.89–3.05)
t2 = 0.00
0.0%
(p =1.00)
All types 52 0.66 (0.31–1.40)
t2 = 0.57
12.2%
(p<0.01)
40 0.66 (0.24–1.84)
t2 = 0.93
16.2%
(p<0.01)
39 1.32 (0.52–3.29)
t2 = 0.86
25.0%
(p<0.01)
87 0.73 (0.40–1.34)
t2 = 0.77
25.3%
(p<0.01)
CI, conﬁdence interval; Inc., including; Exc., excluding.
a Abdominal surgery includes appendectomy, bile duct, liver, or pancreatic surgery, gallbladder surgery, colon surgery, gastric surgery, herniorrhaphy, small and large bowel surgery, spleen surgery, and rectal surgery.
b Cardiac surgery includes coronary artery bypass graft with chest incision with or without donor incision, pacemaker surgery, and thoracic surgery.
c Obstetric and gynaecologic (Obs/Gyn) surgery includes abdominal hysterectomy, ovarian surgery, and vaginal hysterectomy.
d Neck surgery includes thyroid and/or parathyroid surgery.
e Neurological and cranial surgery includes craniotomy and ventricular shunt.
f Orthopaedic surgery includes open reduction of fracture, hip prosthesis, knee prosthesis, limb amputation, spinal fusion, refusion of spine, and laminectomy.
g Transplant surgery includes heart, kidney, and liver.
h Vascular surgery includes abdominal aortic aneurysm repair, shunt for dialysis, carotid endarterectomy, and peripheral vascular bypass surgery.
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Figure 3. Prevalence of Streptococcus agalactiae in isolates from surgical site infection (SSI) after caesarean section (by type of SSI).
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Jodra et al., 2006; Heizmann et al., 2013; Jaaskelainen et al., 2016;
Jones et al., 2003; Li et al., 2016; Merritt et al., 2013; Mir et al., 2011;
Moet et al., 2007; Ray et al., 2013; Zhanel et al., 2010; Behzadnia
et al., 2014). The overall prevalence of GBS in SSTI isolates was
1.89% (95% CI 1.16–3.05%) (Table 3). The pooled prevalence of GBS
was lower in cSSTI (1.02%, 95% CI 0.48–2.15%) than in sources that
did not focus on cSSTI (3.05%, 95% CI 2.00–4.62%) (between-
subgroups p = 0.01) (Figure 5). Sources that included SSI in their
deﬁnition of SSTI yielded a lower prevalence (1.62%, 95% CI 1.00–
2.59%) than those that did not include SSI (3.06%, 95% CI 1.58–
5.84%), but unsupported statistically (p = 0.19). One community-
based study of omphalitis in Pakistan reported GBS in 10.1% (95% CI
7.79–12.9%) of 583 isolates from umbilical stump purulent
secretions (Mir et al., 2011). There was strong evidence
(p < 0.01) in each subgroup of between-study heterogeneity,
contributing a high proportion (I2 = 60–80%) of variance in pooled
estimates. GBS prevalence in SSTI isolates from children (excluding
neonatal omphalitis) was 1.05% (95% CI 0.15–7.09%), compared
with 1.68% (95% CI 0.58–4.78%) in studies that included only adults,
but this difference was unsupported by evidence of between-
subgroup heterogeneity (p = 0.65).
Urinary tract infection
Forty-two sources reporting GBS in UTI were included (Weiner
et al., 2016; European Centre for Disease Prevention and Control
(ECDC), 2013; European Centre for Disease Prevention and Control
(ECDC), 2017; Bouza et al., 2001a; Lee et al., 2004; Jodra et al., 2006;
Phu et al., 2016; Sabra and Abdel-Fattah, 2012; Zhanel et al., 2010;
Behzadnia et al., 2014; Agodi et al., 2013; Alvarez Lerma et al.,
2005; Andreu et al., 2005; Bauserman et al., 2013; Bouza et al.,2001b; Brabazon et al., 2012; Choi et al., 2016; Greenhow et al.,
2014; Guerreiro et al., 2012; Hanna-Wakim et al., 2015; Hayami
et al., 2013; Hedin et al., 2002; Hooton et al., 2013; Karlowsky et al.,
2011; Kazemier et al., 2014; Kiffer et al., 2007; Kronenberg et al.,
2011; Laupland et al., 2007; Lee et al., 2011; Magliano et al., 2012;
Malmartel and Ghasarossian, 2016; Matsumoto et al., 2011;
Monsen et al., 2014; Moulton et al., 2017; Rodriguez et al., 2005;
Sorlozano et al., 2014; Zajac-Spychala et al., 2016; Naber et al.,
2008). GBS was found in 1.09% (95% CI 0.77–1.54%) of UTI isolates,
with a higher prevalence for community (1.61%, 95% CI 1.13–2.30%)
than hospital UTI (0.72%, 95% CI 0.43–1.22%) (between-subgroups
p = 0.01) (Table 4, Figure 6). The prevalence was no higher in
female-only community cohorts (1.51%, 95% CI 0.87–2.62%) than
for both sexes combined (Table 4). GBS accounted for a low
proportion of CAUTI isolates (0.26%, 95% CI 0.24–0.29%) (Figure 7).
The one study that reported a high prevalence of GBS in CAUTI
isolates (8.33%, 95% CI 1.03–27.0%) was in a cohort of women who
had undergone caesarean section (Moulton et al., 2017). Between-
study heterogeneity represented a moderate-to-high proportion of
overall variance (I2 = 40–80%, p < 0.01) for all meta-analyses except
CAUTI (0%).
Respiratory tract infection
Seventeen sources of respiratory tract infection data were
included (Weiner et al., 2016; European Centre for Disease
Prevention and Control (ECDC), 2013; Canadian Antimicrobial
Resistance Alliance (CARA), 2016; Jodra et al., 2006; Phu et al.,
2016; Sabra and Abdel-Fattah, 2012; Zhanel et al., 2010; Behzadnia
et al., 2014; Agodi et al., 2013; Alvarez Lerma et al., 2005; Choi et al.,
2016; El-Kholy et al., 2012; Nizami et al., 2006; Varotto et al., 2001;
Ba-Saddik et al., 2014; Hanna et al., 2006). The prevalence of GBS in
Figure 4. Prevalence of Streptococcus agalactiae in surgical site infection (SSI) isolates after orthopaedic surgery (by type of SSI).
Table 3
Streptococcus agalactiae as a percentage of skin and soft tissue infection (SSTI) isolates.
SSTI deﬁnition Number of estimates included Pooled % prevalence estimate (95% CI) I2 (p-value)
All types 27 1.89 (1.16–3.05); t2 = 0.76 70.4% (p < 0.01)
Complicated vs. non-speciﬁca
Complicated SSTI (cSSTI) 13 1.02 (0.48–2.15); t2 = 0.72 57.4% (p < 0.01)
Not focusing on cSSTI 14 3.05 (2.00–4.62); t2 = 0.32 65.1% (p < 0.01)
Including vs. excluding surgical site infection (SSI)
Including SSI 17 1.62 (1.00–2.59); t2 = 0.37 60.6% (p < 0.01)
Excluding SSI 7 3.06 (1.58–5.84); t2 = 0.57 78.3% (p < 0.01)
CI, conﬁdence interval.
a Skin and soft tissue infections are typically deﬁned as complicated when a surgical intervention is required and/or the infection is suspected or conﬁrmed to involve
deeper soft tissue such as the fascia and/or muscle layers. SSTI may also be considered complicated when it occurs in an immunocompromised patient or with a complicating
comorbidity such as diabetes mellitus, peripheral vascular disease, or peripheral neuropathy.
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was 0.30% (95% CI 0.17–0.52%) (Table 5, Figure 8). Prevalence was
similar for community (0.35%, 95% CI 0.19–0.63%) and hospital RTI
(0.27%, 95% CI 0.15–0.48%) (between-subgroups p = 0.57). There
was evidence of low between-study heterogeneity (I2 = 12–14%) for
all subgroups.
Other types of infection
Two sources reported zero GBS isolates from ear infections:
paediatric conjunctivitis–otitis syndrome (COS), 0/86 middle ear
ﬂuid samples (Bingen et al., 2005); infant otitis media, 0/178
(Husson et al., 2001). Eye infection data were obtained from sixstudies (Stapleton et al., 2007; Bingen et al., 2005; Goh et al., 2010;
Miller, 2017; Morrissey et al., 2004; Truong et al., 2016). Two
studies of keratitis reported zero GBS isolates (out of 59 and 241
isolates) (Stapleton et al., 2007; Truong et al., 2016), as did one
study of corneal ulcer isolates (0/34) (Goh et al., 2010). Two studies
of mixed ocular infections reported GBS prevalence of 0.62% (29/
4649) (Miller, 2017) and 0.19% (1/532) (Morrissey et al., 2004). The
paediatric COS study found no GBS in 466 conjunctival exudate
isolates (Bingen et al., 2005). Based on the ﬁve eye-only sources
(Stapleton et al., 2007; Goh et al., 2010; Miller, 2017; Morrissey
et al., 2004; Truong et al., 2016), the prevalence of GBS in ocular
isolates was 0.16% (95% CI 0.04–0.34%); including COS reduced this
to 0.03% (95% CI 0.00–0.30%).
Figure 5. Prevalence of Streptococcus agalactiae in isolates from skin and soft tissue infections (SSTI).
Table 4
Streptococcus agalactiae as a percentage of urinary tract infection (UTI) isolates.
Settinga Age group Number of estimates included Pooled % prevalence estimate (95% CI) I2 (p-value)
Community + hospital All ages combined 57 1.09 (0.77–1.54); t2 = 0.94 60.1% (p < 0.01)
Community (both sexes) Overall (all ages combined) 30 1.61 (1.13–2.30); t2 = 0.64 79.5% (p < 0.01)
Infants (<4 months) 2 0.61 (0.38–1.00) –
Child 2 0.91 (0.86–0.96) –
Adult (all ages) 12 1.86 (1.05–3.25); t2 = 0.74 78.7% (p < 0.01)
Adult (elderly)b 4 1.63 (0.72–3.64); t2 = 0.35 48.3% (p < 0.01)
Community (female) All ages 12 1.51 (0.87–2.62); t2 = 0.75 68.9% (p < 0.01)
Adult (all ages) 8 1.66 (0.87–3.15); t2 = 0.56 74.6% (p < 0.01)
Adult (elderly)b 1 6.82 (1.43–18.9) –
Hospital (non-speciﬁc + CAUTI) All ages 27 0.73 (0.43–1.23); t2 = 1.04 39.7% (p < 0.01)
Hospital (non-speciﬁc) Overall (all ages combined) 19 0.99 (0.58–1.68); t2 = 0.74 53.2% (p < 0.01)
Infants (<4 months) 3 1.23 (0.72–2.12); t2 = 0.13 –
Child 4 1.09 (0.47–2.51); t2 = 0.47 41.8% (p < 0.01)
Adult 2 2.15 (2.12–2.18) –
Hospital (CAUTI) All ages 8 0.26 (0.24–0.29); t2 = 0.00 0.0% (p = 1.00)
CI, conﬁdence interval; CAUTI, catheter-associated UTI.
a Community UTI specimens either from GP/primary care/outpatient clinic or a hospital inpatient specimen within 48 h of admission; hospital (non-speciﬁc) UTI do not
speciﬁcally exclude CAUTI; 3/6 CAUTI sources were intensive care units (ICU).
b Three quarters of community elderly adult settings were long-term care facilities (LTCF), including the setting for community female elderly adult UTIs.
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This study generated global estimates for the potential role of S.
agalactiae (GBS) as a causative agent of a wide range of community
and healthcare-associated infections. Overall, GBS was isolated
from a small proportion (1%) of SSI and UTI, and a very small
proportion (<0.5%) of RTI. However, GBS was implicated in
noticeably higher proportions of SSI following caesarean section
(3.5% overall, 9.7% of organ/space SSI), vascular surgery SSI (2.4%),
SSTI (1.9%), and community UTI (1.6% overall). GBS also accounted
for slightly higher proportions of SSI after orthopaedic (1.1%) and
breast surgery (1.2%), which is of concern given current andprojected volumes of these procedures (Kummerow et al., 2015;
Kurtz et al., 2007) and the potential seriousness of prosthetic joint
infections (Gundtoft et al., 2017). Estimates based on a small
number of studies for eye and ear infections indicated a very low
proportion of GBS among ocular infection isolates, and no GBS
isolated from ear infections.
The relatively high proportion of caesarean section organ/space
SSI attributable to GBS reﬂects the role of GBS as an important
pathogen in maternal sepsis, causing 15–25% of bacteraemia in
pregnancy and postpartum (Blanco et al., 1981; Drew et al., 2015;
Knowles et al., 2015; Surgers et al., 2013). Studies of post-caesarean
SSI suggest that up to 10% of caesarean sections had a subsequent
SSI (Wilson et al., 2013; Aulakh et al., 2018; Grifﬁths et al., 2005).
Figure 6. Prevalence of Streptococcus agalactiae in isolates from community urinary tract infections (UTI).
Figure 7. Prevalence of Streptococcus agalactiae in isolates from healthcare-associated urinary tract infections (UTI).
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Table 5
Streptococcus agalactiae as a percentage of respiratory tract infection (RTI) isolates.
Settinga Age group Number of estimates included Pooled % prevalence estimate (95% CI) I2 (p-value)
Community + hospital All ages combined 23 0.30 (0.17–0.52); t2 = 0.65 17.1% (p < 0.01)
Child 3 0.19 (0.03–1.32); t2 = 0.00 –
Adult (all ages) 1 0.00 (0.00–0.63) –
Community All ages combined 4 0.35 (0.19–0.63); t2 = 0.00 0.00% (p = 1.00)
Child 2 0.19 (0.03–1.36) –
Hospital (non-speciﬁc + VAP) All ages combined 17 0.27 (0.15–0.48); t2 = 0.59 12.5% (p < 0.01)
Hospital (non-speciﬁc) All ages combined 10 0.45 (0.23–0.88); t2 = 0.44 11.6% (p < 0.01)
Child 1 0.00 (0.00–24.7) –
Hospital (VAP) All ages combined 7 0.17 (0.07–0.39); t2 = 0.43 13.9% (p < 0.01)
Adult (all ages) 1 0.00 (0.00–0.63) –
CI, conﬁdence interval; VAP, ventilator-associated pneumonia.
a Community RTI specimens either from GP/primary care/outpatient clinic or a hospital inpatient specimen within 48 h of admission; hospital (non-speciﬁc) RTI do not
speciﬁcally exclude VAP; 5/7 VAP settings were intensive care units (ICU).
Figure 8. Prevalence of Streptococcus agalactiae in isolates from respiratory tract infection.
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corresponding to national estimates of approximately 850 cases
(including 170 organ/space SSI) after 170 000 annual operations. It
was also noted that the one study that reported a high prevalence
of GBS in CAUTI isolates (8.33%, 95% CI 1.03–27.0%) was in a cohort
of women who had undergone caesarean section (Moulton et al.,
2017). The extent to which a common underlying mechanism of
infection, such as epithelial exfoliation (Vornhagen et al., 2018),
explains ascending infection leading to invasive GBS disease in
pregnancy and also serious postpartum SSI and UTI remains to be
determined. Commonly used and endorsed prophylaxis regimens
(e.g. cefazolin) are generally effective against GBS, and it may be
that utility of and compliance with recommendations needs be
evaluated, including optimal timing of antibiotic administration. In
future, measures to prevent neonatal GBS disease could have the
additional clinical and cost beneﬁt of preventing a signiﬁcantproportion of maternal GBS disease (Kim et al., 2017; Vekemans
et al., 2018).
A trend towards a higher prevalence of GBS by degree of
invasiveness (from superﬁcial to deep to organ/space) was also
evident for orthopaedic, but not abdominal or cardiac SSI, the latter
including donor site incisions. Reasons for these discrepancies, and
for the relatively high prevalence of GBS in breast and vascular SSI,
are unclear. Breast cancer as a risk factor for invasive GBS disease
has been described in two population studies, but as an underlying
disease rather than in relation to surgery (Farley et al., 1993;
Jackson et al., 1995). GBS represented a smaller proportion of SSTI
isolates in studies that focused on cSSTI (1.0%) compared with
studies that did not focus on cSSTI (3.1%). This is the opposite of
what might be expected given an increased risk of invasive GBS
infection in patients with chronic underlying conditions (Sendi
et al., 2008), and if GBS has a proclivity for invasive infection.
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geographic scope and the inclusion of data from several large
surveillance systems. Also, for SSI, common case deﬁnitions (based
on CDC/NHSN criteria) were used by all but one of the included
studies. The main limitations are heterogeneity in case deﬁnitions
for the other types of infections, and heterogeneity and bias in
sampling and laboratory methods. For example, in community and
primary care settings, GBS is more likely to be implicated in the
types of infection, e.g. cystitis, that are treated empirically, with
testing reserved for recalcitrant, e.g. antimicrobial-resistant,
infections that are less likely to be caused by GBS. Or, in settings
where all urine samples are routinely tested, generic culture
methods may not favour the identiﬁcation of GBS. Both of these
factors would underestimate the prevalence of GBS in UTIs. For
wound and SSI we would expect GBS to be detected by routinely
used non-selective culture methods, although the use of non-
selective media could fail to detect GBS in wound infections such as
perineal or groin or peri-anal abscesses where competing
microﬂora can inhibit the growth of GBS in culture (El Aila
et al., 2010; Gupta and Briski, 2004). An example of heterogeneity
between studies is in the healthcare-associated UTI in children
subgroup, where the higher prevalence of GBS in data from New
Zealand may be related to the Auckland District Health Board
providing most of the complex healthcare for New Zealand,
including national paediatric care, meaning that this source of UTI
data will encompass children with high dependency and signiﬁ-
cant co-morbidities.
Hooton et al. reported that the detection of GBS in midstream
urine samples has poor positive predictive value for acute cystitis
(using paired midstream-catheter urine samples from healthy
premenopausal women) regardless of colony count threshold,
although the number of GBS cystitis cases was very small (Hooton
et al., 2013). Given that the majority of UTI studies reported on
midstream urine samples, contamination by colonizing GBS would
inﬂate the prevalence of GBS as a causative agent of UTI in the
present meta-analysis. The misattribution of clinical infection to
colonizing GBS would be more of an issue for superﬁcial incisional,
skin, respiratory, throat, and eye infections than for deep/organ/
space infections, and correcting this bias would reduce GBS
prevalence estimates for these types of infection towards zero.
Where the frequency of GBS was not originally reported in a
published study, the authors’ responses indicated that the actual
frequency was zero vs. non-zero in similar proportions (10/22 zero
vs. 12/22 non-zero). This suggests that the meta-analyses will not
be biased towards over-reporting the prevalence of GBS. Publica-
tion bias is unlikely to affect the study ﬁndings because much of
the data originated from surveillance systems and were purely
descriptive. Some sources did not account for polymicrobial
infections in their denominators, but this would not affect GBS as a
proportion of the total number of isolates unless there was
preferential reporting of particular microorganisms or if GBS in
polymicrobial ﬂora were more likely to be colonizing rather than
infecting; no differences in GBS prevalence by type of denominator
were detected. Some of the surgical categories encompassed a
wide range of procedures within which GBS may have represented
a varying proportion of SSI, e.g. colorectal and bowel operations
within the abdominal surgery category, and coronary artery bypass
graft with or without donor incision surveillance in the cardiac
surgery category. Overall, superﬁcial SSIs are less likely to be
captured by surveillance systems owing to inconsistent use of
community post-discharge surveillance, whereas deep and organ-
space infections frequently result in re-admission to hospital.
In conclusion, although GBS accounts for a relatively small
proportion of SSI and UTI, the absolute numbers of patients with
infections due to GBS will be large. Accurate estimates of GBS
prevalence, particularly for infections such as UTI, which are oftentreated empirically, require studies designed speciﬁcally to detect
GBS, using selective media in unbiased samples of clinical cases.
The relatively high prevalence of GBS in caesarean section SSI
suggests a need for further research with a view to evaluating
current practices concerning surgical antibiotic prophylaxis
administration (choice, timing of delivery of agents) and the
assessment of treatment regimens to ensure use of an agent that
covers GBS.
Funding source
This work was supported by Pﬁzer Inc. The funder had no role in
the study design, data collection, data analysis, data interpretation,
or writing of the report. The corresponding author had full access
to the data in the study and ﬁnal responsibility for the decision to
submit this paper.
Ethical approval
Not required.
Conﬂict of interest
The authors declare no competing interests.
One-sentence summary
Worldwide, group B Streptococcus is implicated in a small
proportion (1–2%) of surgical site, skin and soft tissue, and urinary
tract infections, a very small proportion (<0.5%) of respiratory tract
infections, but a substantial proportion (10%) of invasive surgical
site infections following caesarean section.
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